

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Oakwood Hospital - Southshore</p> <p>2. 5450 Fort Street Trenton, Michigan 48183</p>	<p>In accordance with letter dated March 1, 2015,</p> <p>3. License No. 21-16656-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration Date: September 30, 2021</p> <hr/> <p>5. Docket No. 030-11427 Reference No.</p>
--	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (seeds) (SourceTech Medical, LLC Model STM 1251; International Brachytherapy, Inc. Model 1251L)	D. 1 curie
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed Sources (seeds) (Theragenics Corp. Model 200; International Brachytherapy, Inc. Model 1031L)	E. 1 curie

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
21-16656-01

Docket or Reference No.
030-11427

Amendment No. 22

D. and E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 5450 Fort Street, Trenton, Michigan.
11. A. The Radiation Safety Officer (RSO) for this license (except brachytherapy) is Michael Arsenault, D.O.
B. The Radiation Safety Officer (RSO) for this license for brachytherapy is Talgit Sandhu, Ph.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized User

Material and Use

Sleman A. Khoury, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide iodine-131).

Michael D. Arsenault, D.O.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide iodine-131).

Ronald C. Lutsic, D.O.

10 CFR 35.300 and 35.400.

Choon K. Lee, M.D.

10 CFR 35.400.

Jung H. Chang, M.D.

10 CFR 35.400.

Omar M. Salazar, M.D.

10 CFR 35.400.

Nitin Vaishampayam, M.D.

10 CFR 35.400.

Tai S. Kang, M.D.

10 CFR 35.100 and 35.200.

Bruno F. Borin, D.O.

10 CFR 35.100 and 35.200.

James J. Kochdodan, M.D.

10 CFR 35.100 and 35.200.

Reza Abghari, M.D.

10 CFR 35.100 and 35.200.

David S. Yates, M.D.

10 CFR 35.100, 35.200 and 35.300.

Gregory D. Olson, M.D.

10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
21-16656-01

Docket or Reference No.
030-11427

Amendment No. 22

Authorized User

Material and Use

Jerry W. Drake, M.D.

10 CFR 35.100, 35.200 and 35.300.

Kenneth D. Bartold, M.D.

10 CFR 35.100 and 35.200.

Dong Hyuck Kim, M.D.

10 CFR 35.100 and 35.200.

John H. Finger, M.D.

10 CFR 35.100, 35.200 and 35.300.

Sophia Roumanis, M.D.

10 CFR 35.100, 35.200 and 35.300.

Donald J. Conn, M.D.

10 CFR 35.100, 35.200 and 35.300.

Rob Allen Reed, M.D.

10 CFR 35.100 and 35.200.

Vito A. Casano, M.D.

10 CFR 35.100 and 35.200.

Michael F. Zydeck, M.D.

10 CFR 35.100 and 35.200.

Jeffrey V. Tranchida, M.D.

10 CFR 35.100 and 35.200.

Vladislav Jankulov, M.D.

10 CFR 35.100 and 35.200.

Ashok B. Jain, M.D.

10 CFR 35.100 and 35.200.

Shakuntala B. Rao, M.D.

10 CFR 35.100 and 35.200.

Saleem Azad, M.D.

10 CFR 35.100 and 35.200.

Shameen Menon, M.D.

10 CFR 35.100 and 35.200.

Andre Knoski, M.D.

10 CFR 35.400.

Steven R. Miller, M.D.

10 CFR 35.400.

Jordan M. Maeir, M.D.

10 CFR 35.400.

Josephine J. Finazzo, D.O.

10 CFR 35.100 and 35.200.

Caroline N. Henein, D.O.

10 CFR 35.100, 35.200 and 35.300, limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
21-16656-01Docket or Reference No.
030-11427**Amendment No. 22**

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 20, 2011; and,
- B. Letters dated September 12, 2011, March 19, 2013, March 4, 2014, July 18, 2014, and October 6, 2014.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date APR 17 2015

By


Colleen Carol Casey
Materials Licensing Branch
Region III